Compare GMM & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GMM | BDSX |
|---|---|---|
| Founded | 2017 | 2005 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Precision Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.8M | 122.0M |
| IPO Year | 2022 | 2020 |
| Metric | GMM | BDSX |
|---|---|---|
| Price | $1.13 | $19.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | ★ 175.6K | 149.3K |
| Earning Date | 01-01-0001 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $88,499,000.00 |
| Revenue This Year | N/A | $23.35 |
| Revenue Next Year | N/A | $19.33 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $0.94 | $0.25 |
| 52 Week High | $4.75 | $18.99 |
| Indicator | GMM | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 41.62 | 83.33 |
| Support Level | $1.04 | $6.33 |
| Resistance Level | $1.62 | N/A |
| Average True Range (ATR) | 0.08 | 1.78 |
| MACD | -0.01 | 0.51 |
| Stochastic Oscillator | 14.63 | 100.00 |
Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital asset development for the metaverse industry. The Company leverages its proprietary Mofy Lab technology platform, which integrates three-dimensional (3D) reconstruction technology and artificial intelligence (AI) interactive technology, to create high-definition virtual versions of physical world objects, including humans, animals, and scenes. It provides comprehensive technology solutions to support virtual content production for use across movies, television series, animation, advertising, and gaming. The Company operates through Virtual Technology Services, which generates the majority of revenue, and Digital Asset Development and others.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.